Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 13, 2016 11:00 PM ET

Company Overview of Austen BioInnovation Institute in Akron

Company Overview

Akron, OH 

United States

Founded in 2009

Key Executives for Austen BioInnovation Institute in Akron

Chief Executive Officer and President
Age: 71
Chief Operating Officer
Age: 65
Compensation as of Fiscal Year 2015.

Austen BioInnovation Institute in Akron Key Developments

ADB International Group, Inc. Announces Partnership with Austen Bioinnovation Institute in Akron to Bring E-QURE BST Wound Healing Device to U.S. Market

ADB International Group Inc. announced a partnership with Austen BioInnovation Institute in Akron for the purpose of bringing ADBI's E-QURE BST(TM), a bioelectrical signal therapy device (the E-QURE BST Device), to the U.S. market. The Institute, which has significant expertise in wound healing, clinical trial development and regulatory operations, will conduct a clinical trial that will include 70 patients in a double-arm, controlled, randomized, multi-center study to assess the safety and efficacy of the E-QURE BST Device in subjects with stage II & III Pressure and Venus Stasis ulcers, as an adjunct to the 'Standard of Care'. The company's E-QURE BST Device currently is marketed in Europe for similar indications. It aims to accelerate healing of hard-to-heal chronic wounds by delivering electrical stimulation to an injury site and thus effectively mimicking the electrical currents of chronic wounds in order to enhance the body's natural healing mechanisms. The company's management selected ABIA's Product Innovation and Commercialization Division to spearhead its pre-market clinical trial program, which is necessary to apply for regulatory approval from the FDA to distribute in the United States. ABIA will prepare on behalf of the company an investigative device exemption application to obtain FDA approval to conduct the clinical trials. The initial trial includes 70 patients in a double-arm, randomized, multi-center study to assess the safety and efficacy of E-QURE's BST Device of which data will be submitted to the U.S. Food and Drug Administration to obtain marketing clearance.

Similar Private Companies By Industry

Company Name Region
Rani Properties LLC United States
Fator Securities LLC United States
Skip's Cutting, Inc. United States
Church & Tower Inc. United States
Security Land & Development Co L.P. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Austen BioInnovation Institute in Akron, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.